Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epoprostenol
- Development stage
- Approved
- Lead developer
- Johnson & Johnson
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Epoprostenol is a synthetic form of prostacyclin (PGI2), a naturally occurring prostaglandin. It acts as a potent vasodilator and inhibitor of platelet aggregation. Epoprostenol is primarily used for the treatment of pulmonary arterial hypertension (PAH), where it works by relaxing blood vessels in the lungs and improving blood flow, thereby reducing strain on the heart and improving exercise capacity. The drug is administered intravenously due to its very short half-life. Epoprostenol was first approved under the brand name Flolan in 1995 for PAH[1][3][4][8].
- Brand names
- FlolanVeletri
- Other names
- prostacyclinPGI2PGI-2PGI 2
02
Targets
PTGDR (Prostanoid DP1 receptor)PTGIR (Prostanoid IP Receptor)
Beyond the preview
Go deeper on epoprostenol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epoprostenol.